Materials, Methods, and Systems for Cavitation-mediated Ultrasonic Drug Delivery in vivo

• US 20080319375A1
• Filed: 06/06/2008
• Published: 12/25/2008
• Est. Priority Date: 06/06/2007
• Status: Abandoned Application

• Current Assignee: Biovaluation & Analysis Incorporated
• Original Assignee: Biovaluation & Analysis Incorporated
• Inventors: Hardy, Charles Thomas
• Application Number:
  US12/135,130
• Publication Number:
  US 20080319375A1
• Time in Patent Office: Days
• US Class Current: 604/22
• CPC Class Codes: A61K 41/0028 Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
• CPC Class Codes: A61K 47/6925 the form being a microcapsule, nanocapsule, microbubble or nanobubble
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/5146 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Materials, methods, and systems for targeted and non-targeted therapeutic delivery in vivo utilizing cavitation-mediated ultrasonic drug delivery are described. Noninvasive sonic energy being applied to the patient in a controlled fashion at the treatment area results in controlled acoustic cavitation at said region, and cell and tissue specific drug delivery. Microbubbles, both in the form of contrast agents, and/or other active agents infused into the patient, and/or bubbles formed from previous ultrasound exposure, allow for predictable cavitation thresholds, requiring much lower incident ultrasound intensities for permeating tissue. Further, methods and systems are provided that result in more spatially regular areas of controlled tissue permeability upon treatment, limiting cytotoxicity and sonolysis, and maximizing intracellular drug delivery. Moreover, by using pulsed cavitation-mediated ultrasonic drug delivery as described by the present teachings, a large number of parameters are created, which provided the appropriate monitoring and feedback mechanisms are present, allow the use of a diversity of parameter optimizations and control systems for customizing the methods and systems for a given application. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.

Claims

1. A method suitable for the controlled intracellular and extracellular delivery of one or more therapeutic compounds to a region of a patient, the method comprising the acts (steps) of

(a) administering to the patient one or more therapeutics;

(b) administering to the patient one or more contrast agents;

wherein said contrast agents may be the same as or different from one another;

where steps (a) and (b) are performed

(i) in any order, or

(ii) simultaneously;

(c) alteration of the permeability or structural integrity of said region of said patient comprising

(i) administering to the patient acoustic energy at one or more frequencies, inducing acoustic cavitation at said region of said patient;

(ii) measuring the level of acoustic cavitation at said region of said patient by measuring acoustic emissions either (1) alone;

(2) possibly in combination with one or more additional properties directly or indirectly related to the level of acoustic cavitation at said region of said patient; and

(3) possibly in combination with one or more properties of said acoustic energy;

at the time of or subsequent to the initial application of said acoustic energy;

(d) utilizing the measurement(s) obtained in act (step) (c) to modify continued or subsequent application of acoustic energy to said region of said patient, and possibly administering to said patient one or more additional contrast agents, therapeutics, and other compounds;

wherein said contrast agents, therapeutics, or other compounds may be the same as or different from one another;

where said acoustic energy is applied at a level below the threshold level for lethal sonolysis or cytotoxicity;

(e) allowing said therapeutic compounds to traverse said disrupted cellular membranes and/or other internal structures of said patient, in said region; and

(f) possibly repeating acts (steps) (a) through (e), in whole or in part, either independently or in any combination, one or more times.

2. The method as defined in claim 1, wherein said one or more contrast agents are targeted contrast agents.

3. The method as defined in claim 1, wherein said acoustic emissions include measuring the broadband signal of the spectrum.

4. The method as defined in claim 1, wherein said one or more properties of said acoustic energy measured in act (step) (c) of claim 1 is selected from the group consisting of microbubble backscatter, microbubble backscatter speckle reduction, changes in microbubble backscatter speckle statistics, shear wave propagation changes, electrical impedance tomography, and combination thereof.

5. The method as defined in claim 1, wherein said one or more properties of said acoustic energy measured in act (step) (c) of claim 1 is selected from the group consisting of pressure at one or more frequencies, energy input at one or more frequencies, pulse sequence repetition frequency, pulse sequence content, pulse sequence length, pulse sequence period, duty cycle, and the length of time said acoustic energy is administered.

6. The method as defined in claim 1, wherein said therapeutic compound is contained within or attached to or embedded within a vesicle.

7. The vesicle according to claim 6, wherein said vesicle is a nanocarrier.

8. The nanocarrier according to claim 7, wherein said nanocarrier is comprised substantially of biodegradable triblock copolymers or mixtures thereof.

9. The nanocarrier according to claim 7, wherein said nanocarrier is comprised substantially of branched-chain polymers or mixtures thereof.

10. The nanocarrier according to claim 7, wherein said nanocarrier is comprised substantially of dendritic polymers or mixtures thereof.

11. The nanocarrier according to claim 7, wherein said nanocarrier is comprised substantially of polymersomes or mixtures thereof.

12. The nanocarrier according to claim 7, wherein said nanocarrier is comprised substantially of peptosomes or mixtures thereof.

13. The nanocarrier according to claim 7, wherein said nanocarrier is comprised substantially of supramolecular assemblies or mixtures thereof.

14. The nanocarrier according to claim 7, wherein said nanocarrier is comprised substantially of materials selected from the group consisting of biodegradable triblock polymers, dendritic polymers, polymersomes, peptosomes, supramolecular assemblies, mixtures thereof, and combinations thereof.

15. The method as defined in claim 1, wherein said therapeutic compound is contained within or attached to or embedded within a polymer matrix, such as a hydrogel.

16. The method as defined in claim 6, wherein said vesicle is contained within or attached to or embedded within a polymer matrix, such as a hydrogel.

17. A system for administering acoustic energy to a region of the patient for use in cavitation-mediated ultrasonic drug delivery comprising

(a) one or more transducers with each having one or more array of elements;

(b) a transmitter connected with the transducers, the transmitter operable to both generate an imaging transmission of acoustic energy from one or more arrays, and to generate a therapeutic transmission of pulsed and continuous acoustic energy from one or more arrays;

wherein said therapeutic transmission is below the threshold level of lethal sonolysis or cytotoxicity;

(c) a broadband spectrum analyzer;

(d) possibly one or more geometric (3-axis) positioning systems;

(e) a computer controlled data collection and analyzing system for evaluating information and measurements obtained in act (step) (c), (d), (e), and (f) of claim 1; and

(f) a display or monitor operable to display an image representative of the imaging transmission and one or more characteristics of the data collected and analyzed in (e).

18. The method as defined in claim 1, wherein said acoustic energy is administered to said patient by the system of claim 17.

19. The method as defined in claim 1, wherein said acoustic energy is applied at a frequency between 1 kHz and 10 MHz.

20. The method as defined in claim 18, wherein said acoustic energy is applied at a frequency between 1 kHz and 10 MHz.

21. The method as defined in claim 1, further comprising administering an agent to said patient to enhance diffusion or transport of said therapeutic compounds through said disrupted cellular membranes and/or other internal structures of said patient, in said region.

22. The method as defined in claim 18, further comprising administering an agent to said patient to enhance diffusion or transport of said therapeutic compounds through said disrupted cellular membranes and/or other internal structures of said patient, in said region.

23. The method as defined in claim 1, wherein said acoustic emissions are measured at one or more frequencies other than the frequency or frequencies at which the acoustic energy is applied.

24. The method as defined in claim 18, wherein said acoustic emissions are measured at one or more frequencies other than the frequency or frequencies at which the acoustic energy is applied.

25. The method as defined in claim 1, wherein said acoustic emissions are measured at a frequency, or frequencies corresponding to integer multiples of one-half or one-fourth of the frequency applied.

26. The method as defined in claim 18, wherein said acoustic emissions are measured at a frequency, or frequencies corresponding to integer multiples of one-half or one-fourth of the frequency applied.

27. The method as defined in claim 1, wherein said acoustic emissions are measured at one or more frequencies which do not correspond to peaks in the broadband acoustic spectrum.

28. The method as defined in claim 18, wherein said acoustic emissions are measured at one or more frequencies which do not correspond to peaks in the broadband acoustic spectrum.

29. The method as defined in claim 1, wherein the information and said measurements obtained in claim 1 are analyzed using a mathematical algorithm, such as Fourier Transform or the Fast Fourier Transform.

30. The method as defined in claim 18, wherein the information and said measurements obtained in claim 1 are analyzed using a mathematical algorithm, such as Fourier Transform or the Fast Fourier Transform.

31. The method as defined in claim 1, wherein the application of the acoustic energy is modified in act (step) (d) by changing an acoustic parameter or acoustic energy pulse characteristic selected from the group consisting of pressure, energy, frequency, pulse sequence repetition frequency, pulse sequence content, pulse sequence length, pulse sequence period, total exposure time, duty cycle, and combinations thereof.

32. The method as defined in claim 18, wherein the application of the acoustic energy is modified in act (step) (d) by changing an acoustic parameter or acoustic energy pulse characteristic selected from the group consisting of pressure, energy, frequency, pulse sequence repetition frequency, pulse sequence content, pulse sequence length, pulse sequence period, total exposure time, duty cycle, and combinations thereof.

33. The method as defined in claim 1, wherein the application of the acoustic energy is modified in act (step) (d) by changing an acoustic parameter selected from the group consisting of temperature, fluid gas content, administration rate of molecules to be transported, sample collection rate, device position, and combinations thereof.

34. The method as defined in claim 18, wherein the application of the acoustic energy is modified in act (step) (d) by changing an acoustic parameter selected from the group consisting of temperature, fluid gas content, administration rate of molecules to be transported, sample collection rate, device position, and combinations thereof.

35. The method as defined in claim 1, wherein the application of said acoustic energy is modified by interrupting the application.

36. The method as defined in claim 18, wherein the application of said acoustic energy is modified by interrupting the application.

37. The method as defined in claim 1, wherein the transmitter of said ultrasound system is operable to generate a therapeutic transmission with a single frequency.

38. The method as defined in claim 18, wherein the transmitter of said ultrasound system is operable to generate a therapeutic transmission with a single frequency.

39. The method as defined in claim 1, wherein the transmitter of said system is operable to generate a therapeutic transmission with dual frequencies.

40. The method as defined in claim 18, wherein the transmitter of said system is operable to generate a therapeutic transmission with dual frequencies.

41. The method as defined in claim 1, wherein the transmitter of said system is operable to generate a therapeutic transmission with multiple frequencies.

42. The method as defined in claim 18, wherein the transmitter of said system is operable to generate a therapeutic transmission with multiple frequencies.

43. The method as defined in claim 1, wherein said acoustic energy is composed of cavitation initiating and sustaining sequences.

44. The method as defined in claim 18, wherein said acoustic energy is composed of cavitation initiating and sustaining sequences.

45. The method as defined in claim 1, wherein said therapeutic ultrasound is applied externally to said patient.

46. The method as defined in claim 18, wherein said therapeutic ultrasound is applied externally to said patient.

47. The method as defined in claim 1, wherein said therapeutic ultrasound is applied endoscopically to said patient.

48. The method as defined in claim 18, wherein said therapeutic ultrasound is applied endoscopically to said patient.

49. The method as defined in claim 1, wherein at least one of said therapeutics is administered intravenously.

50. The method as defined in claim 18, wherein at least one of said therapeutics is administered intravenously.

51. The method as defined in claim 1, wherein at least one of said contrast agents is administered intravenously.

52. The method as defined in claim 18, wherein at least one of said contrast agents is administered intravenously.

53. The method as defined in claim 6, wherein said vesicle is administered intravenously.

54. The vesicle according to claim 6, wherein at least one targeting moiety is associated with said vesicle.

55. The targeting moiety according to claim 55, wherein said targeting moiety is comprised of at least one component useful in magnetically targeting said vesicle.